Detection of an imported case of severe Crimean-Congo hemorrhagic fever virus in a patient with comorbidities, Dakar, Senegal 2023.

In July 2023, a diabetic from Mauritania was diagnosed with a severe case of Crimean-Congo hemorrhagic fever at a Dakar region hospital, Senegal. The phylogenetic analysis revealed the new strain as a CCHFV reassortant between Genotype Ⅰ and Ⅲ, closely linked to strains from Spain, Mauritania, Senegal and South Africa. Genetic variability of CCHF in West Africa underscores the urgent need for enhanced surveillance in West Africa. ### Competing Interest Statement The authors have declared no competing interest. ### Funding Statement This study did not receive any funding ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: Data are part of ongoing syndromic surveillance approved by the Senegalese Ministry of Health. The Senegalese National Ethical Committee of the Ministry of Health approved the surveillance protocol which lead to the obtention of human sera as less than minimal risk research, and written consent were not required. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes All data produced in the present study are available upon reasonable request to the authors